Sunesis Pharmaceuticals, Inc. (SNSS) Analysts See $-0.25 EPS; Steinberg Asset Management Has Boosted Xpo Logistics (XPO) Stake By $897,800

February 14, 2018 - By Peter Erickson

Steinberg Asset Management Llc increased Xpo Logistics Inc (XPO) stake by 19.04% reported in 2017Q3 SEC filing. Steinberg Asset Management Llc acquired 13,400 shares as Xpo Logistics Inc (XPO)’s stock rose 7.25%. The Steinberg Asset Management Llc holds 83,764 shares with $5.68M value, up from 70,364 last quarter. Xpo Logistics Inc now has $10.99 billion valuation. The stock decreased 0.69% or $0.635 during the last trading session, reaching $91.635. About 853,342 shares traded. XPO Logistics, Inc. (NYSE:XPO) has risen 103.27% since February 14, 2017 and is uptrending. It has outperformed by 86.57% the S&P500.

Analysts expect Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) to report $-0.25 EPS on March, 8.They anticipate $0.19 EPS change or 43.18% from last quarter’s $-0.44 EPS. After having $-0.43 EPS previously, Sunesis Pharmaceuticals, Inc.’s analysts see -41.86% EPS growth. The stock increased 1.36% or $0.08 during the last trading session, reaching $5.97. About 26,072 shares traded. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has risen 8.33% since February 14, 2017 and is uptrending. It has underperformed by 8.37% the S&P500.

Steinberg Asset Management Llc decreased Fedex Corp (NYSE:FDX) stake by 2,752 shares to 26,076 valued at $5.88M in 2017Q3. It also reduced Aramark (NYSE:ARMK) stake by 13,404 shares and now owns 190,580 shares. Laboratory Corp Amer Hldgs (NYSE:LH) was reduced too.

Investors sentiment increased to 1.83 in Q3 2017. Its up 0.25, from 1.58 in 2017Q2. It increased, as 28 investors sold XPO shares while 76 reduced holdings. 76 funds opened positions while 114 raised stakes. 96.74 million shares or 19.39% more from 81.03 million shares in 2017Q2 were reported. 25,355 are held by Bankshares Of Montreal Can. Ftb invested in 0.03% or 4,100 shares. Moreover, Advsr Asset Mngmt Inc has 0% invested in XPO Logistics, Inc. (NYSE:XPO) for 3,511 shares. Renaissance Tech Limited Liability Corporation has invested 0.02% in XPO Logistics, Inc. (NYSE:XPO). Lonestar Capital Mngmt Ltd Liability Co has 250,000 shares for 3.75% of their portfolio. Dekabank Deutsche Girozentrale has invested 0.05% of its portfolio in XPO Logistics, Inc. (NYSE:XPO). Korea Investment holds 0.1% or 329,100 shares in its portfolio. 6,012 are owned by Prudential Fincl. Private Advisor Limited Company stated it has 0.01% of its portfolio in XPO Logistics, Inc. (NYSE:XPO). Utah Retirement owns 21,400 shares. Fuller & Thaler Asset Mgmt holds 0% or 1,500 shares in its portfolio. Capital Fincl Advisers Limited Liability has 0.14% invested in XPO Logistics, Inc. (NYSE:XPO). Illinois-based Wolverine Asset Mgmt Llc has invested 0.02% in XPO Logistics, Inc. (NYSE:XPO). New Jersey-based Princeton Strategies Grp Incorporated Ltd Liability Corporation has invested 0.09% in XPO Logistics, Inc. (NYSE:XPO). Brown Brothers Harriman And Commerce reported 2,000 shares stake.

Among 21 analysts covering XPO Logistics (NYSE:XPO), 19 have Buy rating, 0 Sell and 2 Hold. Therefore 90% are positive. XPO Logistics had 74 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of XPO Logistics, Inc. (NYSE:XPO) earned “Buy” rating by Credit Suisse on Thursday, January 11. On Monday, January 8 the stock rating was maintained by Susquehanna with “Buy”. The stock has “Outperform” rating by FBR Capital on Friday, August 7. The stock has “Overweight” rating by Morgan Stanley on Tuesday, February 23. JP Morgan initiated XPO Logistics, Inc. (NYSE:XPO) on Monday, July 11 with “Overweight” rating. The rating was maintained by Cowen & Co on Tuesday, May 23 with “Outperform”. Oppenheimer maintained it with “Buy” rating and $7200 target in Wednesday, August 9 report. The firm has “Outperform” rating by Credit Suisse given on Friday, September 29. The firm earned “Buy” rating on Thursday, February 8 by Bank of America. On Tuesday, August 11 the stock rating was maintained by Deutsche Bank with “Buy”.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company has market cap of $204.46 million. The firm is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia . It currently has negative earnings. It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>